In a new note to investors today, an analyst has provided a rating update for the Healthcare company, CannTrust Holdings Inc (TRST). Eight Capital’s analyst Graeme Kreindler expressed some doubt about the stock, as it was downgraded to Sell with a C$4 price target.
According to TipRanks.com, Kreindler is ranked #3876 out of 5238 analysts.
CannTrust Holdings Inc has an analyst consensus of Moderate Buy, with a price target consensus of C$8.83, implying a 151.6% upside from current levels. In a report issued on July 8, Merrill Lynch also downgraded the stock to Sell.
.
Based on CannTrust Holdings Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of C$12.8 million. In comparison, last year the company had a net profit of C$104.9K.
CannTrust Holdings, Inc. engages in the production and distribution of medical cannabis. It focuses on developing nanotechnology to create new products in the medical, recreational, beauty, wellness, and pet markets. The company was founded by Norman Paul and Eric Paul on March 16, 2015 and is headquartered in Vaughan, Canada.
The company’s shares closed on Friday at C$3.51, close to its 52-week low of C$3.50.
